Aratana Gets Rights To Two Compounds For Animal Use

Posted: March 4, 2011, 5:25 p.m., EDT



Published:

Aratana Therapeutics Inc. of Kansas City, Kan., reported today that it has entered into a license agreement with RaQualia Pharma Inc. to develop two compounds from RaQualia’s human clinical development portfolio for companion animal use.

As part of the agreement, Aratana will be granted global rights for development and commercialization of the licensed animal health products. In exchange, the Japanese company will receive upfront payment, development milestones and royalties on global sales.

The first compound is a selective EP-4 antagonist. Aratana reported that the compound has achieved proof of efficacy in human studies and has demonstrated efficacy in animal models for several conditions including, pain, cancer and autoimmune/inflammatory diseases.

The second compound, a selective Ghrelin agonist, has achieved proof of efficacy in human studies and has demonstrated efficacy in animal models for treatment of cachexia and frailty, according to Aratana.

Aratana announced its entry into the animal health industry in early January, which was jump-started by $20 million in Series A financing.


Related story: Aratana Enters Animal Health Industry with $20 Million in Funding

 

 

<Home>

Edit Module
Edit ModuleShow Tags

Archive »Read More

University of Guelph Professor Receives Terry Fox Grant

The grant will go toward testing an innovative vaccine in a canine osteosarcoma clinical trial.

Favorite Vet Contest Called Off Due to Bullying

The issue of cat declawing sparks controversy and the harassment of contest finalists.

DNA Test Digs Deeper Into Dogs’ Background

The Genetic Health Analysis not only identifies ancestral breeds, it raises red flags about potential health problems.

Add your comment:
Edit Module
Edit ModuleEdit ModuleShow Tags Edit Module
Edit Module Edit Module
Edit ModuleShow Tags

Events


Show More...
Edit Module
Edit Module
Edit Module